found that NF2-inactivated meningioma cells were sensitive to Erastin-induced ferroptosis by analyzing 35 meningioma samples (10 NF2 loss and 25 NF2 wildtype), and further confirmed that myoenhancer factor 2C (MEF2C) acted as a promoter of NF2 and CDH1, thereby inhibiting ferroptosis-related lipid peroxidation and meningioma cell death (131). Notably, Kremer et al. The gene discussed is MEF2C; the disease is meningioma.